Results 81 to 90 of about 21,074 (263)
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Amylin analogues as a novel perspective in anti‐obesity therapy
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes.
Kushner P
doaj
Background. Despite the increasing prevalence of emotional overeating and obesity, the specific neurohormonal mechanisms involved in the pathogenesis of these pathological processes remain poorly understood.
N. S. Dedanishvili +3 more
doaj +1 more source
Peripheral targets for neuropathic pain
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour +3 more
wiley +1 more source
Vildagliptin: a new oral treatment for type 2 diabetes mellitus
Chantal Mathieu, Evy DegrandeDepartment of Endocrinology, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell responsiveness to glucose.
Chantal Mathieu, Evy Degrande
doaj
Abstract The incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play critical roles in co‐ordinating postprandial metabolism, including modulation of insulin secretion and food intake.
Constanza Alcaino +2 more
openaire +3 more sources
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo +4 more
wiley +1 more source
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral +3 more
wiley +1 more source
Abstract Aims Rapid changes in diabetes therapy combined with limitations of traditional methodological approaches challenge the field of psychosocial research to adequately capture the experiences of people with diabetes. This narrative review provides an overview of emerging qualitative and quantitative approaches that can advance the study of ...
Dominic Ehrmann +11 more
wiley +1 more source

